Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina ...

While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

Regeneron filed a patent infringement action against Amgen, alleging that Amgen’s ABP 938 would infringe U.S. Patent No. 11,084,865, (the “ʼ865 patent”) directed to an aflibercept formulation useful ...

Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) data for EYLEA HD (aflibercept) Injection 8 mg from an ...

SOL-1 is now expected to be enrolled and fully randomized by year-end 2024Topline clinical data from SOL-1 are now expected in Q4 2025BEDFORD, ...

A 0.4 mg dose of aflibercept in infancy to treat retinopathy of prematurity (ROP) shows sustained efficacy and safety at 3 years of age, according to research presented at EURETINA 2024.

Patients with diabetic macular edema can expect similar BCVA improvements and CST reductions using an aflibercept biosimilar compared with conventional aflibercept. An aflibercept biosimilar is ...

The event will focus on UNITY’s ongoing Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) head-to-head ...

The active ingredient of both agents is aflibercept, already used in the similar medication Eylea, authorized in 2012. However, the CHMP confirmed its refusal of a marketing authorization for ...

On September 19, 2024, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Sandoz’s aflibercept biosimilar AFQLIR.

Further information Decision makers noted that Aflibercept 8mg is clinically equivalent and of at least equal cost-effectiveness to the NICE recommended aflibercept 2mg formulation (TA 346 and TA294).